Table 5. Association of positive ranges of p53 expression, TP53 gene mutation, and the incidence of regional lymph node metastasis and/or postoperative recurrence in patients with endometrial endometrioid carcinoma.
| % of p53 expression | No metastasis | Metastasis | Total mutation | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Cases | Mutation | Cases | Mutation | ||||||
| 0–9% | 95 | N/A | 7 | (6.9%) | N/A | N/A | |||
| 10–19% | 14 | 2/12 | (16.7%) | 8 | (36.4%) | 1/6 | (16.7%) | 3/18 | (16.7%) |
| 20–49% | 6 | 1/2 | (50.0%) | 5 | (45.5%) | 0/5 | (0%) | 1/7 | (14.3%) |
| 50–79% | 4 | 3/4 | (75.0%) | 5 | (55.6%) | 1/5 | (20.0%) | 4/9 | (44.4%) |
| 80–100% | 6 | 3/4 | (75.0%) | 4 | (40.0%) | 2/2 | (100%) | 5/6 | (83.3%) |
| Total | 125 | 9/22 | (40.9%) | 29 | (18.8%) | 4/18 | (22.2%) | 13/40 | (32.5%) |
Incidence of metastatic and/or recurrent disease: 0–9 vs. 10–19%, p<0.01. 10–19 vs. 20–49%, NS. 20–49 vs. 50–79%, NS. 50–79 vs. 80–100%, NS. 10–19 vs. 80–100%, NS.
N/A, not available. NS, not significant.